

Curriculum Vitae

Medical Director/Clinical Investigator

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53rd Street, Temple Terrace, FL 33617
 Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

Research & Professional Experience:

MOORE Clinical Research, Inc, Medical Director/Clinical Investigator	May 2020-Present
MOORE Clinical Research, Inc, Clinical Investigator	March 2018-May 2020
Clearwater Free Care Clinic, Internist, Clearwater, Florida	June 2016-Present
Private Practice, Scott Miller MD PLLC, Charleston, West Virginia	April 1991-March 2015

Education and Postdoctoral Training:

Cardiovascular Medicine Fellowship, Marshall University, Huntington, WV	July 1989-June 1992
Medical Doctor in Medicine, Internal Medicine Residency, West Virginia University School of Medicine	June 1978-June 1989

Licenses/Certifications/Memberships:

State of Florida Medical License ME 130209	January 2020
Fellow, American College of Internal Medicine, Board Certified	Initial 1989
Fellow, American College of Cardiovascular Disease, Board Certified	Initial 1991
Bloodborne Pathogens & Biomedical Waste Management 29 CFR OSHA Regulations	August 2020
BLS for Healthcare Providers, American Heart Association	March 2020
Academy of Physicians in Clinical Research (APCR)	June 2018

Training:

Comprehensive SOP Review	January 2020
Bloodborne Pathogens & Biomedical Waste Management	August 2019
Comprehensive SOP Review	January 2019
14 th Annual Coastal Dermatology Symposium, Monterey, CA	October 2018
KOH Wet Mount and Mycology Sample Collection and Interpretation	July 2018
Adverse Event Collection and Reporting in Clinical Research	June 2018
Acne Vulgaris Rater Training and Validation	April 2018
Bloodborne Pathogens & Biomedical Waste Management	March 2018
Comprehensive SOP Review	March 2018
Responsible Conduct of Research, CITI Program	March 2018
Good Clinical Practice, NIH Training	March 2018
Human Subject Assurance Training	March 2018

Clinical Trial Experience:

Cardiovascular Clinical Trials: NIH Multicenter Veterans Administration, 1982, metoprolol in acute myocardial infarction, Sub-Investigator NIH Multicenter Veterans Administration, 1989, transdermal nitroglycerin patch in angina, Sub-Investigator

ACNE VULGARIS (Validated Acne Rater)

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.1% (XXXX) to Differin Gel (Adapalene 0.1% XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2020, Sub-Investigator

Note: Electronic signature for this document is a Part 11 compliant signature produced via RealTime CTMS eDOCS

Curriculum Vitae

Medical Director/Clinical Investigator

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53rd Street, Temple Terrace, FL 33617
Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Tretinoin Cream 0.025% (XXXX) to Retin-A® (Tretinoin) Cream 0.025% and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2019, Principal Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clindamycin Phosphate Topical Lotion 1% (XXXX) to Clindamycin Phosphate Topical Lotion 1% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2019, Principal Investigator

"A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle Controlled Study of XXXX in the Treatment of Acne Vulgaris." 2019, Principal Investigator

"A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Dapsone Gel, 7.5% (XXXX) to Aczone® (Dapsone) Gel, 7.5% (XXXX) and Both Active Treatments to A Placebo Control in the Treatment of Acne Vulgaris." 2019, Principal Investigator

"A Phase 2, Randomized, Multicenter, Double-Blind, Vehicle Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of VB-1953 Topical Gel When Applied Daily for 12 Weeks in Subjects with Facial Acne Vulgaris for Treatment of Moderate to Severe Inflammatory Acne Vulgaris" 2019, Principal Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clindamycin Phosphate Topical Gel 1% (XXXX) to Cleocin T (Clindamycin Phosphate Topical Gel 1% XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2019 Principal Investigator

"A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy Of IDP-120 Gel And IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris." 2018, Principal Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% (XXXX) to Differin® (XXXX, Adapalene Gel 0.3%) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2018, Principal Investigator

"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of XXX XXX and Clindamycin Phosphate Lotion, 1% in Subjects with Acne Vulgaris." 2018 Principal Investigator

"A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study, Comparing Clindamycin 1% to Cleocin T (XXXX, Clindamycin 1% Gel) and Both Active Treatments to a Vehicle Control in the Treatment of Acne." 2018, Sub-Investigator

"A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris." 2018, Sub-investigator

ACTINIC KERATOSIS

"A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream 5%, With Efudex (5-FU) Cream 5%, and Both Active Treatments to a Vehicle Control, in the Treatment of Actinic Keratosis." 2018, Principal Investigator

ASTHMA

"A Randomized, Blinded, Multiple-Dose, Placebo-Controlled, Multi-Center Study Comparing Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg to QVAR® 40 mcg (beclomethasone dipropionate HFA), Inhalation Aerosol in Treatment of Subjects with Asthma." 2018, Sub-Investigator

ATOPIC DERMATITIS

"A Phase II, Randomized, Double-Blind, Vehicle Controlled Study of the Efficacy, Safety, and Tolerability of B244 Topical Spray for the Treatment of Pruritis in Adults with a History of Atopic Dermatitis." 2020, Sub-Investigator

Note: Electronic signature for this document is a Part 11 compliant signature produced via RealTime CTMS eDOCS

Curriculum Vitae

Medical Director/Clinical Investigator

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53rd Street, Temple Terrace, FL 33617
Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

"A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Multiple Intravenous Doses of FB825 in Adults with Atopic Dermatitis." 2020, Sub-Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Doxepin Hydrochloride Topical Cream, 5% (XXXX) to Doxepin Hydrochloride topical cream, 5% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate Pruritis in Adults with Atopic Dermatitis." 2019, Sub-Investigator

"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis." 2018, Sub-Investigator

COMMON COLD

"A Phase 3, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of colds due to Enterovirus/Rhinovirus infection." 2018, Sub-Investigator

INFLUENZA

"A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza." 2018, Sub-Investigator

PSORIASIS

"An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of XXX-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis." 2020, Principal Investigator

"A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Proof of Concept Comparison Study of the Safety and Efficacy of DUR-928 Topical Solution with Occlusion in Subjects with Mild to Moderate Plaque Psoriasis." 2019, Principal Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Calcipotriol and Betamethasone Dipropionate Topical Gel 0.005%/0.064% (XXXX) Dovobet® Gel (Calcipotriol and Betamethasone Dipropionate Gel) 0.005%/0.064% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Mild to Moderate Body Plaque Psoriasis Vulgaris." 2018, Principal Investigator

"A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of XXXXX in Subjects with Moderate-to-Severe Plaque Psoriasis." 2018, Principal Investigator

"A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients with Moderate-Severe Plaque Psoriasis.: 2018, Principal Investigator

"A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis." 2018, Principal Investigator

"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 24-Week Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate) Extended Release Tablets in Subjects with Moderate-to-Severe Plaque Psoriasis." 2018, Sub-Investigator

ROSACEA

Note: Electronic signature for this document is a Part 11 compliant signature produced via RealTime CTMS eDOCS

Curriculum Vitae

Medical Director/Clinical Investigator

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53rd Street, Temple Terrace, FL 33617
Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Ivermectin Cream 1% (Taro Pharmaceuticals USA, Inc) to Soolantra (Ivermectin) Cream 1% and Both Active Treatments to a Placebo Control in the Treatment of Moderate to Severe Facial Rosacea." 2020, Sub-Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study, Comparing Ivermectin Cream 1% (XXXX) to Soolantra® (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate to Severe Facial Rosacea." 2019, Sub-Investigator

"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Ivermectin Cream 1% (XXXX) to XXXX (Ivermectin) Cream 1% (XXXX) in the Treatment of Moderate to Severe Papulopustular Rosacea." 2017, Sub-Investigator

"A Randomized, Multi-center, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea." 2017, Sub-Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Azelaic Acid Foam 15% (XXXX) to Finacea (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate Facial Rosacea." 2017, Sub-Investigator

SCALP PSORIASIS

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension 0.005%/0.064% (XXXX) to Talconex® (Calcipotriene Hydrate and Betamethasone Dipropionate) Topical Suspension 0.005%.0.064% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Scalp Psoriasis." 2018, Principal Investigator

"An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment with Desoximetasone 0.25% shampoo (XXXX U.S.A., Inc.) in Patients with Scalp Psoriasis." 2016, Sub-Investigator

TINEA PEDIS

"A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutics Equivalence of Ketoconazole Cream 2% (XXXX) to Ketoconazole 2% (XXXX) in the Treatment of Tinea Pedis." 2019, Principal Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clotrimazole and Betamethasone Dipropionate Cream 1%/0.064% (XXXX) to Lotriderm (Clotrimazole and Betamethasone Dipropionate) Cream 1%/0.064% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Tinea Pedis." 2018, Principal Investigator

"A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (XXXX) to Ketoconazole Cream 2% (XXXX) in the Treatment of Tinea Pedis." 2018, Principal Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study, Comparing Naftifine HCL Gel 2% (XXXX) to Naftin (Naftifine HCL) Gel, 2% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Tinea Pedis." 2017, Sub-Investigator